Valuation: Ind-Swift Laboratories Limited

Market Cap 31.24B 329M 293M 272M 247M 465M 473M 3.26B 1.28B 16.28B 1.23B 1.21B 51.99B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 27.03B 285M 253M 235M 214M 402M 409M 2.82B 1.11B 14.09B 1.07B 1.05B 44.98B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
33.96%
Yield 2025 *
-
Yield 2026 -
1 day+0.36%
1 week-0.46%
Current month-7.59%
1 month-5.02%
3 months+55.20%
6 months+172.45%
Current year+307.54%
1 week 345
Extreme 345
377.2
1 month 345
Extreme 345
424.75
Current year 87.25
Extreme 87.25
424.75
1 year 87.15
Extreme 87.15
424.75
3 years 68.72
Extreme 68.72
424.75
5 years 52.65
Extreme 52.65
424.75
10 years 15
Extreme 15
424.75
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%-0.46%+254.46%+293.05% 329M
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average -0.12%+3.21%+56.41%+84.43% 394.12B
Weighted average by Cap. +0.13%+3.83%+39.35%+71.84%

Financials

2025 2026
Net sales 5.62B 59.16M 52.64M 48.82M 44.38M 83.64M 84.96M 586M 230M 2.93B 222M 217M 9.35B 6.49B 68.37M 60.83M 56.42M 51.29M 96.66M 98.18M 677M 266M 3.38B 257M 251M 10.8B
Net income 2.5B 26.38M 23.47M 21.77M 19.79M 37.3M 37.88M 261M 103M 1.31B 98.99M 96.88M 4.17B 431M 4.54M 4.04M 3.75M 3.41M 6.42M 6.52M 44.95M 17.66M 225M 17.04M 16.68M 718M
Net Debt -4.27B -44.92M -39.97M -37.08M -33.7M -63.52M -64.52M -445M -175M -2.22B -169M -165M -7.1B -4.21B -44.37M -39.48M -36.61M -33.28M -62.73M -63.71M -439M -172M -2.2B -166M -163M -7.01B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
26-10-16 ₹359.25 +0.36% 309,979
26-10-15 ₹357.95 -3.18% 262,152
26-10-14 ₹369.70 +2.31% 354,561
26-10-13 ₹361.35 +0.08% 365,436
26-10-12 ₹361.05 +0.04% 305,213
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock